Abstract:  Objective To conduct health economic evaluation analysis for trabectome, canaloplasty and to analyze the budget impact of applying for prices of trabectome. Design  health economics evaluation. Participants 3 patients diagnosed as primary open-angle glaucoma that underwent day case anti-glaucoma surgery in February 2022 with completed 12-months-follow-up in Peking University Third Hospital. Methods The evaluated effectiveness was measured by the success rate of the surgical procedures. The evaluated cost was the direct medical costs of surgeries and post operationally follow-up within 12 months. The minimum cost analysis was used to compare trabectome with canaloplasty, while the cost-effectiveness analysis was used by calculating the incremental cost-effectiveness ratio (ICER) to compare both trabectome and canaloplasty with trabeculectomy, respectively. The difference in total costs of various types of surgery before and after the price application for trabectome was calculated based on the amount of canaloplasty and trabeculectomy, as well as the substitution of trabectome. Main Outcome Measures Success rate of the surgical procedures, direct medical costs, ICER. Results The total cost per case for trabectome and canaloplasty was ￥13729 and ￥28793, respectively, which showed an ￥15064 decrease in cost from tebectome to canaloplasty. Using the total cost per case of ￥14281for trabeculectomy as a reference, the ICER was -￥87.6 for trabectome and ￥767.8 for canaloplasty. Prospectively replacing at least 50% of canaloplasty and trabeculectomy with trabectome, the total cost of the hospital was saved by￥384080 annually. Conclusion In Beijing, trabectome was more cost-effective than canaloplasty and trabeculectomy for primary open-angle glaucoma. The total costs of surgical treatment relevant for primary open-angle glaucoma could be saved after the price of trabectome was applied. (Ophthalmol CHN, 2024, 33: 193-199)

Key words: glaucoma, health economics